

What is claimed is:

1. An antisense compound 8 to 50 nucleobases in
5 length targeted to nucleobases 96-523 of a coding region of
a nucleic acid molecule encoding human superoxide dismutase
1, soluble (SEQ ID NO: 3), wherein said compound
specifically hybridizes with and inhibits the expression of
human superoxide dismutase 1, soluble (SEQ ID NO: 3).
- 10 2. The compound of claim 1 which is an antisense
oligonucleotide.
3. The compound of claim 2 wherein the antisense
oligonucleotide comprises at least one modified
internucleoside linkage.
- 15 4. The compound of claim 3 wherein the modified
internucleoside linkage is a phosphorothioate linkage.
5. The compound of claim 2 wherein the antisense
oligonucleotide comprises at least one modified sugar
moiety.
- 20 6. The compound of claim 5 wherein the modified
sugar moiety is a 2'-O-methoxyethyl sugar moiety.
7. The compound of claim 2 wherein the antisense
oligonucleotide comprises at least one modified nucleobase.
8. The compound of claim 7 wherein the modified
25 nucleobase is a 5-methylcytosine.
9. The compound of claim 2 wherein the antisense
oligonucleotide is a chimeric oligonucleotide.
10. A method of inhibiting the expression of
superoxide dismutase 1, soluble in brain and spinal cord,
30 comprising intraventricularly administering to an animal a
compound 8 to 50 nucleobases in length targeted to a
nucleic acid molecule encoding superoxide dismutase 1 so
that expression of superoxide dismutase 1, soluble is
inhibited.